London-based HighQ has formed a vendor partnership with the SAFE-BioPharma Association. Companies within the global pharmaceutical and biotechnology industry use the SAFE-BioPharma standard in FDA Title 21 CFR part 11 compliant processes for signing SOPs, quality and compliance documentation, research and development documentation, corporate compliance documents and more.
HighQ provides the life sciences industry with a unified space for secure document exchange and social collaboration across a global network of employees, researchers and partners – both internal and external to the company. HighQ Collaborate, a secure cloud-based platform, allows users to disseminate information to discovery teams, CROs, investigators and business development partners worldwide. Users will have the opportunity to securely exchange documents using their SAFE-BioPharma digital identities on the HighQ Collaborate platform, ensuring their credentials are available anytime and anywhere.
"By making use of collaborative tools such as wiki pages and blog posts alongside traditional office software (Word, Excel, PowerPoint, PDF etc.), sponsors, CROs and investigators can work more efficiently, eliminating the time consuming need to print out physical documents that require signatures during clinical trials. By partnering with the SAFE-BioPharma Association, HighQ will enable the life sciences industry to have an efficient, enforceable and regulatory-compliant document approval process, whilst facilitating secure document exchange and social collaboration throughout the organization," said Jacob Mathew, consultant – KM Practice, HighQ.
